To provide a CCR4 function control agent useful for preventing and treating diseases such as bronchial asthma and atopic dermatitis.

This CCR4 function control agent comprises a compound represented by formula (1) [wherein, the ring A represents a heterocyclic group; the ring B represents a carbon ring, a heterocyclic group, or the like; P1 and P2 are CH or N; (q) and (r) are each 0 to 2; X is -NH-, -O-, or -CH2-, or the like; Y is -CH2-, -CO-, -SO2- or the like; Z is -CO-, -SO2-, or the like; R3 is a carbon cyclic group, a heterocyclic group, an hydroxy group, an alkoxy or amino] or its pharmaceutically acceptable salt.